We have demonstrated rapid inhibition of GLI1 and GLI2 binding to target gene promoters (1 hr), reduced reporter activity specific to GLI-luciferase, and rapid inhibition of gene transcription in human colon carcinoma cell lines [37]. The gene discussed is GLI1; the disease is colon carcinoma.